Why I No Longer Like Polynovo (ASX: PNV) Shares
Polynovo has a great product, but the company has much leadership turmoil for my taste.
Company Coverage
4 Key Risks Keeping Me Out Of Acusensus Shares (ASX:ACE)
Acusensus (ASX: ACE) is leading road rule enforcement company. The revenue growth is attractive but I hesitate over a few key risks.
Australian Ethical Investments (ASX: AEF) H1 FY 2025 Results Show Strong Earnings Per Share Growth
The results were good but the company could suffer from lower equity markets.
Vysarn (ASX: VYS) H1 FY 2025 Results Analysis
Vysarn (ASX: VYS) has a lot of moving parts, and not all are growing.
SiteMinder (ASX: SDR) 1H FY25 Half-Year Results Analysis
The company is still growing revenue but free cash flow generation and profit margins are tracking below expectations.
AUB Group (ASX: AUB) H1 FY 2025 Results Analysis
AUB Group (ASX: AUB) boasts a resilient business model and an excellent track record of dividend growth over the long term.
RPM Global (ASX: RUL) Revenue Up But Profit Down In H1 FY 2025 Results
The long term thesis remains on track and the current share price weakness looks like a potential opportunity to me.
Why I Will Sell My AF Legal Shares (ASX: AFL)
3 reasons I will sell my shares in AF Legal after considering the half-year report.
Dicker Data (ASX: DDR) Shows Green Shoots In 2024 Full Year Results
Dicker Data (ASX: DDR) showed a strong profitability improvement in the second half of its CY 2024 reporting year.
Monash IVF (ASX: MVF): Growth Strategy Shifts In H1 FY 2025 Result
Monash IVF (ASX: MVF) shifts from acquisitions to organic growth, eyeing Victoria’s recovery, global expansion, and cost efficiencies to drive future gains.
Kip McGrath Education Centres (ASX: KME) H1 FY2025 Result: The Good, the Bad and the Tutorfly
The KME H1 FY 2025 results showed modest revenue growth, improved profit, and a strengthening balance sheet.
Polynovo (ASX: PNV) Disappoints Market With H1 FY 2025 results
Doctors love Polynovo’s Novosorb BTM and Novosorb MTX products, but the market hated its H1 FY 2025 results.
Energy One (ASX: EOL) Share Price Zooms Up 50% On Record H1 FY 2025 Results
The Energy One (ASX: EOL) share price has reacted strongly to its return to profitability in H1 FY 2025.
IPD Group (ASX: IPG) Reports Impressive H1 FY 2025 Results: But Are There Gremlins Under The Surface?
IPD Group (ASX: IPG) reported decent results and the IPD Group share price has moved up slightly, despite weak commercial construction.
XRF Scientific (ASX: XRF) Share Price Gains On Solid H1 FY 2025 Results
Solid results from a company that just keeps on delivering growth.
Netwealth (ASX: NWL) Posts Record Inflows, But Can It Maintain the Momentum?
Netwealth (ASX: NWL) posts record inflows, hitting $101.6B FUA. Can it sustain momentum as legacy platforms decline?
An Introduction To Pharmx (ASX:PHX) After Its H1 FY 2025 Results
I will be keeping an eye on the PharmX (ASX: PHX) share price because the PharmX business model seems to have the potential to scale nicely.
Audinate (ASX: AD8) H1 FY 2025 Results: Has The Worst Passed?
Growth Gauge has long followed Audinate shares, and is expecting more optimism in the future, after the undeniably tough H1 FY 2025 results were released.
BSA Ltd (ASX:BSA) Director Sold Shares Before 80% BSA Share Price Fall
The BSA Ltd share price fell 83% yesterday.
HUB24 (ASX: HUB) Share Price Gains On Record H1 FY 2025 Results
It’s easy to tell the H1 FY 2024 Hub24 (ASX: HUB) results were good. But I’m less confident that there is still value on offer after the stock has doubled in price.